UroGen Pharma Says ZUSDURI Shows Durable Disease-Free Outcomes at Three Years
MT Newswires Live
May 13
UroGen Pharma's (URGN) ZUSDURI treatment demonstrated a 64.5% 36-month duration of response in the pivotal ENVISION Phase 3 trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, the company said Wednesday.
The company said the median duration of response had not yet been reached at a median follow-up of 35.5 months, with 79.6% of patients achieving a complete response at three months and many remaining disease-free at three years based on Kaplan-Meier analysis.
The data support the durability of ZUSDURI without maintenance therapy, highlighting its potential as a non-surgical, in-office to repeated transurethral resection of bladder tumor procedures, UroGen Pharma added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.